Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT-1 study of repotrectinib in ROS1- or NTRK-rearranged advanced solid tumors
CTR20202412Phase 2Active
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of repotrectinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), central nervous system primary tumor, sponsored by Turning Point Therapeutics, Inc.. Started May 2021; status: active.
02
Drugs
repotrectinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)central nervous system primary tumor
Beyond the preview
Go deeper on CTR20202412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202412.